statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nanatinostat combined with valganciclovir shows promising results in treating relapsed or refractory EBV+ peripheral T-cell lymphoma, demonstrating higher efficacy and tolerability than nanatinostat...

Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?

The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy...

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on iTeos Therapeutics (ITOS Research Report), Viracta Therapeutics...

Analysts Are Bullish on These Healthcare Stocks: iTeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)

Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from...

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX  Get Free Report) traded down 8.4% during trading on Thursday . The stock traded as low as $0.76 and last traded at $0.82. 190,182 shares were...

Viracta Therapeutics (NASDAQ:VIRX)  Shares Down 8.4%

Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter...

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...

Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public...

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viracta Therapeutics (VIRX Research Report) and Pa...

Wall Street Analysts Are Bullish on Top Healthcare Picks

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Viracta Therapeutics provides anticipated 2024 milestones

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Watchers	13,040
52-Wk Low	$0.43
52-Wk High	$2.38

Volume	40,061.00
52-Wk High	$2.38
52-Wk Low	$0.43

VIRX Viracta Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals